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INTRODUCTION 
“Thus the creation of a cancer cell is thought to involve a sequence of events 
of which perhaps only the early steps bear any direct relation to the interaction 
between mutagen and DNA. This is borne out by the observation that the later 
events can be caused by other agents (promoters) that are not themselves 
mutagenic.” 
John Cairns (1981) [l] 
MOST HUMAN cancers are triggered or propagated by exposure to environmental agents. 
Carcinogenesis is an expression of a complex interplay between exogenous factors that 
may be inhaled, ingested, or absorbed through the skin, and the evoked responses in the 
host that are under genetic control. Conversion of a normal cell to neoplastic pheno- 
type involves molecular activation and expression of transforming genes. Transformation 
of a normal cell to a cancer cell represents a self-perpetuating programming error, a 
genetic malfunctioning of the integrated control systems for cell proliferation and 
differentiation. 
The “sudden” clinical expression of a malignant neoplasm obscures recognition that 
symptomatic cancer is the phenotypic endpoint of a sequence of molecular and biochem- 
ical events occurring over an induction-latency period measured in years. In experimental 
systems, the length of the latency period varies with the type and dose of the tumorigenic 
agent, intrinsic susceptibility of target cells modulated by host immunogenetic character- 
istics, and tumor growth kinetics. The natural history of neoplastic development evolves 
through stages of initiation, promotion and autonomous progression. Initiation is a 
stochastic, multistep process that involves one or more generally irreversible, heritable 
alterations in the basic structure of cellular DNA that may have been induced by such 
diverse factors as genotoxic chemicals, ionizing radiation or oncogenic viruses. As defined 
by Farber [2], promotion is the “process whereby an initiated tissue. . develops focal 
proliferations, one or more of which may act as precursors for subsequent steps in the 
carcinogenic process.” The rate of progression of promotional steps in response to 
exogenous and endogenous growth promoting factors is dose dependent and may exhibit 
a measurable threshold as well as a maximal response. The critical molecular events are 
associated with selective proliferation and altered gene expression. The phenotypic features 
of autonomous progression are exponential growth, increased invasiveness, and alterations 
in the biochemical, morphologic, and karyotypic characteristics of the neoplasm [3]. 
Various multistage and multihit quantitative models for carcinogenesis have been 
proposed to accommodate a conceptual framework for interpreting experimental and 
epidemiological data. A highly desirable property of a model would be that it enables 
testing or validation through experimentation and human observational study. The 
effective use of mathematical models requires an appreciation of underlying biologic and 
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mathematical principles. Multistage models have been proposed to fit or predict age- 
specific incidence patterns for human cancers, and to provide a mechanistic framework for 
interpreting the dynamic features of malignant cell transformation in the context of the 
inherent growth kinetics of normal target tissue. 
UNIFYING CONCEPT OF CARCINOGENESIS 
“. .diversity of input and commonality of output.” 
Emmanual Farber (1982) [2] 
A multistage model of carcinogenesis implies that more than one rate determining step 
is necessary to transform a normal cell into a cancer cell. In most such models, age-specific 
incidence is proportional to the product of the rate’constants for each transformational 
and evolutionary stage. In the two-stage (mutation) model of carcinogenesis advanced by 
Moolgavkar and Knudson [4], the clonal origin and stem cell evolution of cancer, and the 
nature and number of mutations are basic concepts concerning genetic events critical to 
human tumor development. A clonogenic stem cell model system of carcinogenesis 
postulates that damage to DNA results in the loss of normal control and regulation of 
stem cell proliferation and differentiation which disturbs the dynamic balance of transi- 
tional cell production, stem cell self-renewal, terminal differentiation and cell loss in target 
tissue. 
Boveri [5] deduced from his studies of sea urchin development in the early 1900’s that 
a malignant tumor originated from a single cell. He concluded that this aberrant somatic 
cell, as a result of mitotic error, acquired an abnormal chromosome constitution as an 
intervening primary event in tumor development. In a contemporary context. one or more 
of the stages in carcinogenesis may be viewed as involving heritable alterations in gene 
structure and function. The multifactorial causes of human cancers appear to impact upon 
a genetically responsive substrate within the cell. 
Proto-oncogene activation 
A series of discoveries within the past 10 years have begun to illuminate the molecular 
basis of human neoplasia. Oncogenes, previously thought to exist exclusively in animal 
tumor viruses such as the RNA retroviruses and DNA papovaviruses, have apparently 
been carefully preserved throughout vertebrate evolution. DNA sequences that have been 
identified in retroviral one genes are homologous to segments present in normal human 
cellular DNA and in tumor cell DNA. The presence of homologous DNA sequences in 
both human tumors and viral transforming genes is of considerable interest. since 
information about the biochemistry and mechanisms of action of oncogenic retroviruses 
may shed light on the molecular evolution of human tumors. The human genome contains 
a relatively limited number of structurally and functionally distinctive genes designated as 
proto-oncogenes that presumably function in normal cell division and growth. The 
proto-oncogenes are widely distributed throughout the human genome and appear to be 
strategic targets for perturbation by carcinogens [6]. 
Dissection of the human genome has revealed at least 20 cellular proto-oncogenes. 
Different subgroups or families of cellular proto-oncogenes and oncogenes appear to exert 
different or distinctive effects through their encoded proteins. The experimental approaches 
employed to identify the structure and function of human and animal cellular oncogenes 
include exploiting mechanisms by which retroviruses acquire sequences of host DNA, and 
performing transfection assays of cellular DNA in NIH/3T3 mouse fibroblast cells. Using 
restriction enzyme techniques, DNA may be progressively broken down into fragments 
that are analyzed for in z;itro transformation capabilities. The structure of the transforming 
oncogene may then be identified by means of nucleic acid hybridization to radioactive 
probes and cloned by means of recombinant-DNA technology [7]. 
Enhancement of human proto-oncogene activity may occur through the insertion 
of retroviral DNA, or, more commonly, somatic mutational events that do not involve 
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Mechanism 
TABLE 1. MECHANISMS OF PROTO-ONCOGENE ACTlVATlON 
PVXCSS Consequence 
Amplification Increase I” number of 
copies of oncogene 
Chromosomal markers of homogeneously staining regions and double 
minute chromosomes; 
Increased level of messenger RNA; 
Enhanced malignant growth potential; 
Examples of proto-oncogene amplification in human cancer cell lines: 
c-myc m small cell lung cancer; 
N-myc in neuroblastoma, and r-erb B-l in glioblastoma multiforme 





Mechamsm for chemotherapy resistance of cancer cells 
Deregulation of translocated c-myc from chromosome 8, Burkitt’s 
lymphoma, and of translocated c-abl from chromosome 9, chrome 
myelogenous leukemia; 
Deletion of repressive genes, as on chromosome 3, small cell carcinoma 
lung; chromosome 13, retinoblastoma; chromosome I I, Wilms’ tumor 





Increased messenger RNA as in c-mos proto-oncogene-murine plasma- 




Base mutation in 
coding sequences 
Integration of proviral 
DNA segment, as in 
retroviral activation 
Alteration in DNA 
codon 
Enhanced transcriptional activity: Ha-ras (rat); myc and erb B, avian 
hempatopoietic neoplaslas 
New gene product with altered activity, as in c-ras, the homologue of 
Harvey murine sarcoma virus, associated with human carcinomas 
the integration of viral DNA. The various molecular mechanisms of proto-oncogene 
activation may serve to initiate and promote somatic evems that evolve sequentially 
along a common pathway of tumorigenesis (Table 1). Activated oncogenes have been 
detected by transfection focal assays in DNA preparations from human carcinomas of 
the bladder, lung, breast, pancreas, colon and prostate, and neuroblastomas, leukemias, 
lymphomas and sarcomas. Other transforming genes will undoubtedly be isolated in 
tumor-DNA preparations from human solid tumors, leukemias and lymphomas, although 
such discoveries may require transfection to recipient cells other than mouse fibro- 
blasts. The abnormal transforming activity within a DNA sequence, as shown by 
recombinant-DNA technology, may result in part from a single base change or point 
mutation in a codon that corresponds to an alteration in one amino acid, or from 
heightened transcription or overproduction of messenger RNA as a result of insertional 
gene rearrangement [8]. 
Tumorigenesis is a multistep process, which may involve cooperative interaction 
between different proto-oncogenes and the elaboration of transforming growth factors. 
The protein products of some of the cellular oncogenes appear to be linked with growth 
regulation, as suggested by the analysis of nucleotide sequences that are homologous to 
the normally present platelet-derived growth factor or epidermal growth factor [9]. Indeed, 
it is the concept of unregulated autocrine secretion of growth factors that may provide an 
explanation for the autonomous proliferation of cancer cells [lo]. In addition to proto- 
oncogenes, there are likely to be other classes of gene alterations, such as anti-oncogenes 
and modulating genes, as well as epigenetic events, which affect the origin, expansion and 
progression of human cancers. 
Knudson [l l] proposed that cancer may arise when two genes at a critical locus are 
inactivated. His two-mutation model for the origin of cancer was developed initially to 
explain familial and non-familial retinoblastoma. In hereditary retinoblastoma, the mutant 
or deleted locus, 13q14, with linkage to the locus for esterase D activity, is inherited in 
an autosomal dominant pattern. The somatic retinal cells of the person inheriting the 
mutation are heterozygous, but phenotypically appear normal. The second step would be 
somatic inactivation by various mechanisms of the remaining normal allele. In sporadic, 
non-familial retinoblastoma, both loci are affected by somatic mutational events. A similar 
phenomenon has been interpreted for Wilms’ tumor, with deletion of the 11~13 locus. The 
familial form of retinoblastoma, in contrast to the non-familial, is manifested by earlier 
1024 DAVID SCHOTTENFELD 
age at onset, and greater tendency for bilaterality, multicentricity, and associated 
radiation-induced bone sarcomas [ 121. 
It is the absence of normal gene function in the 13q14 region that predisposes to 
retinoblastoma. Comings [13] suggested that expression of a proto-oncogene, particularly 
in the hereditary cancers, might involve an inherited mutation of a regulatory gene, or 
anti-oncogene. Subsequent somatic mutation for the homologous regulatory gene might 
lead to loss of suppression of the transforming gene and, hence, tumor development. The 
natural history of retinoblastoma has served as the prototypic model for implication of 
the presence of anti-oncogenes or “suppressor” genes. The anti-oncogene operates in a 
recessive mode, because one normal allele is sufficient to protect against the expression of 
risk for a particular cancer. This is in contrast to the mechanism of action of an oncogene, 
in which a normal or slightly altered gene functions inappropriately or in an augmented 
fashion, unresponsive to normal regulatory signals [14]. 
CHROMOSOMAL FRAGILE SITES AND GENE REARRANGEMENTS 
“There is little doubt that genomes of some if not all organisms are fragile and 
that drastic changes may occur at rapid rates. These can lead to new genomic 
organizations and modified controls of type and time of gene expression.” 
Barbara McClintock (1978) [ 151 
Genomic changes of various kinds, such as base substitutions, deletions and dupli- 
cations, amplifications and rearrangements through reciprocal translocations or inversions 
are characteristic of malignant neoplastic cells. With the methotrexate cell synchronization 
high-resolution banding technique, chromosomal defects have been identified in most 
patients with leukemia or lymphoma, and with increasing frequency in various solid 
tumors in children and adults [16, 171. 
Chromosomal instability and fragility may be viewed as an intrinsic expression of the 
neoplastic process. Such rearrangements occur at sites that regulate transcription of 
oncogenes, or within segments of DNA that, as a consequence, encode altered proteins 
with abnormal mitogenic activity [ 181. 
Chronic myelogenous leukemia 
Nowell and Hungerford [19] reported in 1960 that a specific chromosome abnormality, 
later designated as the Philadelphia or Ph’ chromosome was consistently associated with 
chronic myelogenous leukemia. This discovery was made possible by a technical inno- 
vation in cytogenetics, even before banding, whereby hyposmotic treatment of cells 
enabled better spreading of metaphase chromosomes. Chronic myelogenous leukemia is 
a myeloproliferative disorder characterized by abnormal proliferation of hematopoietic 
precursor cells, the clonal progeny of a single neoplastic stem cell. The stem cell is affected 
by reciprocal translocation involving chromosomes 9 and 22. The Philadelphia chromo- 
some, which is demonstrable in 90-95% of patients with chronic myelogeneous leukemia, 
results from the exchange of distal segments of each chromosome. In situ chromosomal 
hybridization has revealed that the breakpoint on chromosome 9 is close to band q34 
where the abl oncogene is located. The abl oncogene rearranges with gene bcr from 
chromosome 22, producing an abnormal transcript, an abl-bcr hybrid RNA, which is 
translated into an abnormal protein with tyrosine kinase activity. The activation of the 
oncogene in its translocated setting contributes to a selective growth advantage of the 
affected cell [20]. 
Burkitt ‘s lymphoma 
The first clinical and pathological description of Burkitt’s lymphoma was published 
more than 25 years ago [21]. This B-cell lymphoma is the most common cancer of children 
in areas of both East and West Africa, although it has a low incidence world-wide. Burkitt 
lymphoid tumor cell lines consistently exhibit a reciprocal translocation of chromosome 
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8 with either chromosome 14 (75%), 22 (16%) or 2 (9%). Chromosomes 14, 22 and 2 
contain coding sequences that are involved in immunoglobulin production. With the use 
of a radioactively labeled probe containing genetic sequences almost identical with the 
u-myc oncogene of the avian myelocytomatosis virus, which is causally linked with a B-cell 
lymphoma in chickens, it was determined that a homologous human c-myc oncogene was 
located within the breakpoint band of chromosome 8q24.1. Thus, the juxtaposition in 
B-lymphocytes of an oncogene (c-myc) to the encoding sequences for heavy chains 
(chromosome 14) or light chains (chromosomes 2 or 22) of antibody molecules reflects a 
cytogenetic aberration with pathogenic implications. Translocation of the oncogene alters 
its normal regulatory control, enhances functional transcription, and ultimately facilitates 
B-cell malignant transformation [22]. 
The epidemiologic features of Burkitt’s lymphoma have suggested a multi-stage model 
of pathogenesis. The Epstein-Barr viral genome has been identified in cultured tumor cells 
in more than 90% of the cases in Africa where the disease is endemic. In contrast, where 
the disease occurs sporadically, the Epstein-Barr virus has been identified in 15-20% of 
cases. Primary infection of B lymphocytes with the Epstein-Barr virus may serve in most, 
but not all instances, to stimulate a polyclonal B-cell proliferation, a necessary precursor 
event in B-cell neoplastic conditions. Other chronic infections, such as falciparum malaria 
and/or associated immune deficiency disorders, sustain a high turnover of the lymphocyte 
population. The ultimate monoclonal neoplastic conversion is signaled by cytogenetic and 
molecular events that have been described previously [23,24]. 
TUMOR PROMOTERS IN HUMAN CARCINOGENESIS 
“The natural history of the development of human neoplasia is not dis- 
tinguishably different from that in animal models.” 
Roswell K. Boutwell (1985) [25] 
We have previously considered how loss or alteration of regulatory genes may be 
accompanied by augmented expression of cellular oncogenes, and that these molecular 
events comprise steps in a common pathway leading to malignant transformation. All too 
often the initiating trigger for such a cascade of events is unknown, although epidemiologic 
research has identified a varied spectrum of lifestyle and environmental causative factors 
(Tables 2 and 3). 
As emphasized by Boutwell [25], although humans are exposed inevitably to carcino- 
genic agents, both the dose level of a putative initiator in combination with the dose level 
of exposure to one or more promoting agents determine the rate of development and 
clinical presentation of malignant tumors. At least three different stages have been defined 
in the development of neoplasia in experimental systems: initiation, promotion, and 
progression. 
The classical two-stage mouse skin model has shown that epidermal tumors can be 
induced by the sequential application of a single subcarcinogenic dose of a polycyclic 
aromatic hydrocarbon (initiation stage), followed by repetitive applications with another 
class of agent, such as croton oil or a phorbol ester (promotion stage). A single large dose 
of the initiator, such as 7, 12_dimethylbenz(a)anthracene (DMBA), without the application 
of any other agent, is capable of inducing skin tumors in mice. Papillomas appear initially 
within l&20 weeks, and carcinomas subsequently within 20-60 weeks. Thus, the applica- 
tion of a very high dose of a carcinogen may lead both to initiation and promotion of 
tumorigenesis. A single reduced subcarcinogenic dose of DMBA will not give rise to 
tumors over the lifespan of the mouse, unless it is followed by repeated applications of 
a promoting agent. Multiple sequential applications of the promoter without, or prior to, 
initiation by DMBA does not give rise to epidermal tumors. After the initiation phase, 
the tumor response is ultimately the same, whether the promotional stage is initiated one 





TABLE 2. MAJOR NOC-OTCUPATIONAL ENVIROUMI~U’TAL CAUSES “fi CANCER 1~ THE UNITED STATPS 
Organ site(s) Comments 
Contributes to 25 ~35% of all cancer deaths in men, 5--10% in Larynx. lung, oral cavity, 
pharynx, esophagus. 
pancreas, kidney, urmary 
bladder 
women. g&85% of lung cancer deaths. Within the oral cavity. all 
forms of tobacco smoke and smokeless tobacco are of etlologic 
sigmficance; to the extent that tobacco juice ib swallowed. the 
extrinsic larynx and esophagus are affected. Combmatlon exposures 
of tobacco with alcohol. asbestos. and ionizing radiation (radon 
alpha particles) m uramum miners lead to multiplicative effects. For 
example, miners who have smoked a pack of cigarettes a day for 20 
years have radiation-induced lung cancer rates per unit of exposure 
that are about five times those m miners who do not smoke. 
Tobacco smoke consists of more than 3,600 mdlvidual compounds, 
with the major tumorigenic activity contained in the particulate 
matter of “tar” fraction. Examples of carcinogenic agents include the 
polynuclear aromatic hydrocarbons and nitrosamines. 
Contributes to 3% of all cancer deaths. Tobacco and alcohol 
combined account for about 75-85% of upper digestive tract cancer 
mortahty. Possible mechanisms of co-carcinogenic actlon include the 
following: 
Alcohol 
Ionizmg radiation Hematopoietic, breast, 
bone, thyroid, lung, 
esophagus, stomach, colon, 
urinary bladder, connective 
tissue 


















Oral cavity, pharynx, 








Liver, uterine cervix(?) 
Lymphoreticular, skin. soft 
tissue 
Kidney pelvis 
Local cytotoxlcity affectmg mucosal permeability; 
Presence of low levela of carcinogens in alcohohc beverages (e.g., 
fuel, oils, polycyclic aromatic hydrocarbons, nitrosamines); 
Induction of microsomal enzymes that activate procarcinogens in 
remote and target tissues; 
Alcohohc hver inJury may affect important mechamsms’of chemical 
detoxification; 
Nutritional deficiencies (e.g.. wtamins A. C, riboflavin. and iron) 
gwe rise to altered mucosal integrity, enzyme and metabolic dys- 
function. and morphologic abnormalities; and 
Decreased immune responsiveness. 
Natural background radiation may account for 1.5% of all cancer 
deaths; occupational exposures and medical uses of ionizing radiation 
(gamma, beta, and X-rays) account for about I%. The most radio- 
sensitive tissues are the female breast, thyroid. and hematopoietic 
tissues. The mm~mal latency period for solid cancers is about IO yr; 
and for leukemia, about 2 yr. 
Of major concern are the u.v.-B radiations (29&320 nm). Skm cancer 
is predominantly a disease of the white race and is rare in deeply 
pigmented ethnic and racial groups. In nonmelanoma skin cancer. 
lesions occur primarily on parts of the body with direct chronic 
exposure; outdoor workers are at greater risk than indoor workers; 
incidence is greatest in areas of high msolation and is inversely corre- 
lated with latitude. The solar etiology of malignant melanoma IS 
more consistent with intermittent intense exposures, rather than 
correlated with chronic cumulatwe exposure. Melanoma incidence is 
not correlated with outdoor work, IS particularly high in upper 
managerial and professional employment categories, and, m contrast 
with squamous carcmoma of the skin, is not significantly age- 
dependent. Host factors, such as the familial dysplastic news syn- 
drome and acquired immune dysfunction, may serve as predisposing 
or enhancing characterwcs. 
Various medications account for about I% of all cancer deaths. 
The alkylating agents are cytotoxic, mutagemc, electrophllic, and 
clastogenic. 
DES acts as a transplacental carcmogen. When administered over a 
period of years to patients with gonadal dysgenws, DES haa been 
associated with adenosquamous carcinoma of the endometrlum 
The synthetic estrogens and progestins used in many oral contra- 
ceptives are 17 alpha alkyl substituted steroids similar in structure to 
the androgenic anabohc steroids. The combination oral contraceptives 
are significantly protective with respect to carcmomas of the endo- 
metrium and ovary, but do not alter the risk of breast cancer, even 
among high-risk subgroups. In contrast, studies have suggested that 
the risk of uterine cervical dysplasia and carcinoma may be increased 
by longterm use of oral contraceptives. 
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TAeLE 2-mmtinued 




Epstein-Barr wrus and 
malaria are co-factors 
Nasopharynx: Epstein- 
Barr virus 








retrovirus-Types I, II 
Uterine cervix:? 
Herpes simplex 






Dietary deficiencies Oral cavity, esophagus, 
and excesses stomach, colon, pancreas 





Viral oncogenic agents probably account for 5 10% of cancer deaths. 
The relative importance of each biologic agent varies throughout the 
world. 
The human T-cell lymphotropic retrovirus Type III IS transmmed 
by sexual contact or by contaminated blood products or needles. 
Increased risk of mahgnant lymphoma, with origin m central nervous 
system or Burkitt-type lymphoma. 
International comparisons of site-specific cancer mortality, the 
“experiments of nature” prowded by migrant studies and case- 
control studies have suggested that a substantial etiologic fraction 
of some of the major cancer sites in the United States may be 
attributable to dietary factors. Thus, it has been estimated that 
through dietary modifications we might ultimately achieve a 35% 
reduction in cancer mortality. Various nutrition hypotheses have 
been concerned with excess in dietary fat consumption and the role 
of obesity with respect to the incidence of cancers m the colon, 
endometrium, breast, and gallbladder, or with deficiencies in fresh 
fruits and vegetables with respect to the risk of various gastroint- 
estinal tract cancers. 
Pollutants in urban air have long been suspected in the etiology of 
lung cancer, with fossil fuel combustion products, especially poly- 
cyclic hydrocarbons, being of special concern. Some studies have 
suggested that tobacco smoke may interact with carcinogens in the 
ambient atmosphere, or that neighborhood communities may be 
alTected by airborne pollutants (e.g. asbestos, arsemc, radon) from 
Industrial sources. Interest has also centered on contaminants in 
drinking water, since several halogenated organic compounds (tri- 
halomethanes) produced during chlorination are carcinogenic or 
mutagenic on laboratory tests. Levels of these compounds m surface 
drinking water have been positively correlated with mortality rates 
for cancers of the bladder and large bowel. The attribulable risk has 
been difficult to estimate with any precision, but probably does not 
exceed l-2%. 
Modified after Schottenfeld D: Arch Environ Health 39: I5C-I 57, 1984. 
The two-stage model system in mouse skin has been generalized to other mouse organ 
systems, such as the liver, lung, colon, urinary bladder, mammary gland, stomach, 
esophagus, pancreas, mouse cell culture systems, and the rat tracheal organ culture system. 
The critical molecular events in tumor promotion are associated with a mitogenic effect 
and altered gene expression in initiated stem cells [27]. 
Various biochemical mechanisms have been explored to clarify the action of different 
classes of tumor promoters. Promoting agents differ in their effects on different target 
tissues, and in different animal species. The phorbol esters, for example, induce multiple 
biochemical effects such as: (a) alteration of cell membrane glycoprotein structure and 
enzyme activity; (b) stimulation of growth-promoting substances such as proteases, 
polyamines and prostaglandins; (c) formation of free radicals and activated oxygen; (d) 
increased turnover of phospholipids; and (e) induction of the enzyme ornithine decar- 
boxylase, which is the rate-limiting enzyme for synthesis of the polyamines putrescine, 
spermidine and spermine. While it has been recognized that oxygen radicals and peroxides 
participate in radiation carcinogenesis, it has also been demonstrated that reactive oxygen 
species are important mediators of chemical toxicity in tumor promotion. Other examples 
of tumor promoters are contained within the diet, bile acids, food additives, steroid 
hormones, phenobarbital, cigarette smoke and asbestos [28]. 
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rat Used extensively I” mdustry as a solvent and a starting 
mice(?) material or intermediate in production of cyclic hydro- 
human carbons. An estimated 3 million workers are potentially 
(primarily. exposed. OSHA regulation for a permissible exposure 
acute non- limit is IO ppm in air for a” X-hour time-weighted 
lymphocytic average. Chromosomal aberrations and aplastic anemia 




Aromatic amine used as a” intermediate in the pro- 
duction of dyes. An estimated 2200 workers are 
potentially exposed. Annual productton has decreased 



















at site of 
Injection) 
mouse, rat 










Formerly used as a rubber antIoxidant and as a dye 
intermediate 
Over 95% of arsemc produced in the Unisted States IS 
;L by-product of copper and lead ore smelting. Excess 
lung cancer has been reported in association with 
use and production of Inorganic trivalent arsenic- 
containing pesticides as well as metal smelting oper- 
atiom. An estimated 545,000 workers are potentially 
exposed. Occupation Safety and Health Administration 
(OSHA) standard for limiting occupational exposure is 
IOpg,‘m’. 
The four commercially important forms are chrysotile, 
amoslte. anthophyllite, and crocidolite. Chrysotile repre- 
sented 94% of United States production and consumptm” 
I” the 1970s. About 2.5 million workers are estimated to 
have some exposure. Combined cigarette smoking and 
asbestos exposure increase lung cancer risk multlplicat- 
wely. Asbestos exposure in the United States accounts for 
approximately 5% of lung cancer deaths and l-2% of all 
cancer deaths in me”. OSHA standard is 2 fibers/cm’ of 
a,r for fibers longer than 5 pm. 
Used industrially as a dye or dye intermediate for color- 
ing textiles. leather, and paper. Approximately 3000 
workers are potentially exposed. 
Used in the manufacture of plastics and ion exchange 
resins. No estimates are available for number of workers 
exposed 
Used in metal alloys, electroplating, magnetic tapes, 
pigment for paints, cement, rubber, composition floor 
covenng, and as oxidant in synthesis of organic 
chemicals. An estimated 2.5 million workers are exposed 
10 chromium and its compounds. OSHA regulation has 
adopted g-hour time-weighted average exposure limits 
of 0.5 mg/m’ for soluble chromium compounds, I mg/m’ 
for chromium metal and insoluble compounds and expo- 
sure level of 0.1 mg/m’ for chromic acid and hexavalent 
chromates. 
Complex mixture of products of coal combustion and 
distillation comprised of polycyclic aromatic hydrocarbons 
OSHA has estimated that 10,000 workers are exposed to 
these emissions. OSHA standard of exposure is I50 pg/m’ 
averaged over any &hour period. 
lngestmn and inhalatm” of dusts which contain iron 
oxides, silica, and eve” radon. The contrtbution of factors 
other than ferric oxide to increased lung cancer mortahty 
I” the underground hematite miners is unknown. 
Conlinuetl 
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TABLE 3 - conrimed 
Animal and 
Epidemiologic 































































The strong sulfuric acid process in the manufacture of 
isopropyl alcohol leaves a residue of isopropyl oils and 
diisopropyl sufate and dlethyl sulfate. It is not clear 
whether one or more of these substances is a respiratory 
tract carcinogen. The primary commercial uses of iso- 
propyl alcohol are in acetone production and as a solvent 
or chemical intermediate. About 141.000 workers are 
potentially exposed to the isopropyl manufacturing pro- 
cess in the United States. 
Mustard gas was used in chemical warfare during World 
War I, and production and stockpiling of this chemical 
was maintained during World War II. It has been tested 
as a prototype compound for antineoplastic alkylating 
agents. Lung cancer mortality increased among workers 
with chronic exposures. 
Used principally as an intermediate in the manufacture of 
dyes and as an antioxidant in the rubber industry. Little 
commercial production in the United St&es during the 
past IOyr 
Used in electroplating, manufacturing of steel and other 
alloys, ceramics, storage batteries, electric circuits, petro- 
leum refining, and oil hydrogenation. An estimated 
710.000 workers are potentially exposed. OSHA standard 
is 0.007 mg/m’ for mckel carbonyl and 1 mg/m’ for metal 
and soluble compounds. 
These substances result from fossil fuel processing tech- 
nology, and represent mixtures of aromatic hydrocarbons. 
Precise risk varies with nature of mixture and nature 
and route of exposure (i.e. skin absorption, inhalation, 
ingestion). 
Principal use is in production of plastics, packaging 
materials, and vinyl asbestos floor tiles. More than 3.5 mil- 
lion workers are potentially exposed. Its use as an aerosol 
propellant was banned by the EPA, FDA, and CPSC. 
OSHA standard is 1 ppm as an 8-hour time-weighted 
average and a 5 ppm ceiling for any 15-minute period. 
Reprinted with permission of the pubhsher: Arch Environ Health 39: 15s-157, 1984. 
INHERITANCE OF CANCER SUSCEPTIBILITY 
“Cancer is essentially a genetic disease at the cellular level.” 
W. F. Bodmer (1982) [29] 
A major objective of molecular studies of carcinogenesis would be to determine the 
location of genes involved in modulating susceptibility, and to establish biochemical and 
immunologic mechanisms of pathogenesis. The existence of genetically determined patho- 
logic conditions, or even more subtle metabolic processes, that alter our ability to cope 
with environmental mutagens, should challenge the epidemiologist to view the carcino- 
genic process as a complex and dynamic interaction of environment and heredity [30]. 
Indeed, “ecogenetics”, or the study of genetic variability in response to specific environ- 
mental agents, is analogous to the concern in pharmacogenetics of host variability with 
respect to therapeutic response, toxicity, metabolism and biotransformation. The ultimate 
outcome of exposure to potential carcinogens may depend on competitive geneenzyme 
interactions that affect activation or detoxification, or on the integrity of endogenous 
mechanisms for repairing lesions in DNA [31, 321. 
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